Lu Linwei, Xu Qianzhu, Wang Jun, Wu Sunyi, Luo Zimiao, Lu Weiyue
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China.
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Shanghai 201203, China.
Pharmaceutics. 2022 Apr 6;14(4):797. doi: 10.3390/pharmaceutics14040797.
Drug nanocrystals, which are comprised of active pharmaceutical ingredients and only a small amount of essential stabilizers, have the ability to improve the solubility, dissolution and bioavailability of poorly water-soluble drugs; in turn, drug nanocrystal technology can be utilized to develop novel formulations of chemotherapeutic drugs. Compared with passive targeting strategy, active tumor-targeted drug delivery, typically enabled by specific targeting ligands or molecules modified onto the surface of nanomedicines, circumvents the weak and heterogeneous enhanced permeability and retention (EPR) effect in human tumors and overcomes the disadvantages of nonspecific drug distribution, high administration dosage and undesired side effects, thereby contributing to improving the efficacy and safety of conventional nanomedicines for chemotherapy. Continuous efforts have been made in the development of active tumor-targeted drug nanocrystals delivery systems in recent years, most of which are encouraging and also enlightening for further investigation and clinical translation.
药物纳米晶体由活性药物成分和少量必需稳定剂组成,能够提高难溶性药物的溶解度、溶出度和生物利用度;反过来,药物纳米晶体技术可用于开发化疗药物的新型制剂。与被动靶向策略相比,活性肿瘤靶向给药通常通过修饰在纳米药物表面的特异性靶向配体或分子实现,它规避了人体肿瘤中微弱且异质性的增强渗透与滞留(EPR)效应,克服了非特异性药物分布、高给药剂量和不良副作用等缺点,从而有助于提高传统纳米化疗药物的疗效和安全性。近年来,在活性肿瘤靶向药物纳米晶体递送系统的开发方面不断取得进展,其中大多数成果令人鼓舞,也为进一步研究和临床转化提供了启示。